Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ironwood Pharma Files to Begin China Phase III Trial of Linaclotide

publication date: Jul 17, 2012
Ironwood Pharmaceuticals has filed a Clinical Trial Application with the SFDA for a China Phase III trial of linaclotide. Linaclotide is a peptide agonist aimed at treating abdominal pain in patients with irritable bowel syndrome accompanied by constipation. Ironwood, a Massachusetts pharma, still owns the China rights to the drug, although it has partnered linaclotide for much of the rest of the world. More details....

Stock Symbol: (NSDQ: IRWD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital